Blueprint Medicines Corp (NAS:BPMC)
$ 97.37 5.49 (5.98%) Market Cap: 6.19 Bil Enterprise Value: 5.60 Bil PE Ratio: 0 PB Ratio: 19.71 GF Score: 79/100

Blueprint Medicines Corp to Discuss the Global Collaboration with Roche to Develop and Commercialize Pralsetinib for Patients with RET-Altered Cancers Call Transcript

Jul 14, 2020 / 12:00PM GMT
Release Date Price: $79.97 (+4.33%)
Operator

Ladies and gentlemen, thank you for standing by and welcome to the Blueprint Medicines Update Conference call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker for today, Kristin Hodous of Blueprint Medicines. You may begin.

Kristin Hodous
Blueprint Medicines Corporation - Senior Manager of IR

Thank you, operator. Good morning, everyone. This is Kristin Hodous of Blueprint Medicines, and welcome to Blueprint Medicines' Update Call. This morning, we issued a press release regarding our collaboration with Roche to update and commercialize pralsetinib. You can access the press release as well as the slides that we'll be reviewing today by going to the Investors section of our website at www.blueprintmedicines.com.

Today on our call, Jeff Albers, our Chief Executive Officer; and Kate Haviland, our Chief Operating Officer, will provide a summary of the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot